{"id":"cd1a3332200d","type":"article","url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","title":"AF en ICD bij niet-ischemische HFrEF: impliciaties voor devicetherapie","title_en":"Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["hfpef","hfref"],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euaf200","source_url":"https://doi.org/10.1093/europace/euaf200","authors":["Seiko N Doi","Adelina Yafasova","Jens Jakob Thune","Jens C Nielsen","Niels E Bruun","Lars Videbæk","Hans Eiskjær","Christian Hassager","Jesper H Svendsen","Dan E Høfsten","Steen Pehrson","Lars Køber","Jawad H Butt"],"significance":5,"published":"2025-09-01","source_date":"2025-09-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/icd-bij-hartfalen/"],"congress":"","summary_en":"Analysis of the DANISH trial examined the impact of atrial fibrillation on ICD outcomes in non-ischaemic heart failure with reduced ejection fraction. AF influenced the ICD indication and the risk of inappropriate shocks, informing device therapy decisions.","created":"2026-07-03T10:31:50Z","updated":"2026-07-03T13:30:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie onderzocht de impact van AF op ICD-uitkomsten bij niet-ischemische HFrEF. AF beïnvloedt de ICD-indicatie en het risico op inappropriate shocks.","abstract_original":"AIMS: Atrial fibrillation (AF) is associated with an increased risk of sudden cardiac death. Therefore, the effect of an implantable cardioverter-defibrillator (ICD) may be greater in patients with AF. We examined the long-term effects of primary prevention ICD implantation vs. usual clinical care according to AF status in DANISH. METHODS AND RESULTS: Outcomes were analysed according to AF status at baseline (history and/or on enrollment ECG). The primary outcome was all-cause death, and secondary outcomes were cardiovascular and sudden cardiovascular death. Of the 1116 patients with non-ischaemic heart failure with reduced ejection fraction randomized in DANISH, 418 (37.5%) had AF at baseline, of whom 24.2% had paroxysmal AF, 17.0% persistent AF, and 58.9% permanent AF. AF status did not significantly modify the effect of ICD implantation on all-cause death, although there was a suggestion of a greater effect in patients with [hazard ratio (HR) 0.78 (95% CI, 0.59-1.03)] vs. without AF [HR 0.98 (0.75-1.27)] (Pinteraction = 0.15). AF status significantly modified the effect of ICD implantation on cardiovascular death, such that ICD implantation was associated with a lower rate of this outcome in patients with AF [HR 0.67 (0.48-0.94)], but not in those without AF [HR 1.04 (0.76-1.41)] (Pinteraction = 0.04). Although AF status did not significantly modify the effect of ICD implantation on sudden cardiovascular death, there was a suggestion of a greater effect in patients with [HR 0.45 (0.24-0.82)] vs. without AF [HR 0.76 (0.41-1.38)] (Pinteraction = 0.20). CONCLUSION: In the DANISH trial, the presence of AF was associated with a greater effect of ICD implantation on cardiovascular death, and although similar trends were observed for all-cause and sudden cardiovascular death, the treatment-by-subgroup interaction was not statistically significant for these outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov; unique identifier: NCT00542945."}